BeStock  
Stocks › Biotechnology › ABUS

Arbutus Biopharma ABUS

US equityMarket cap rank #3471Biotechnology
$4.02 −$0.05 (-1.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.98 -1.00%
Open$4.01
Prev close$4.07
Day range$3.97 – $4.09
Volume2.99M
Market cap$616.24M
P/E (TTM)3.6
Dividend yield–

Earnings

Average move on report day±3.5%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+10.1%
Worst reaction-13.7%

Stock move on the day after each report

-4.5%2021/Q4+2.4%2022/Q1+3.3%2022/Q2-0.8%2022/Q3+0.0%2022/Q4+1.6%2023/Q1-1.0%2023/Q2-1.6%2023/Q3-2.8%2023/Q4-0.4%2024/Q1+1.1%2024/Q2-1.0%2024/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2024/Q36 Nov 2024Pre Market±13.4%-1.01%Within range
2024/Q21 Aug 2024Pre Market±16.4%+1.06%Within range
2024/Q12 May 2024Pre Market±14.4%-0.37%Within range
2023/Q429 Feb 2024Pre Market±24.3%-2.78%Within range
2023/Q37 Nov 2023Pre Market±16.0%-1.60%Within range
2023/Q23 Aug 2023Pre Market±12.0%-0.96%Within range
2023/Q14 May 2023Pre Market±23.9%+1.59%Within range
2022/Q42 Mar 2023Pre Market±33.6%+0.00%Within range
2022/Q39 Nov 2022Pre Market±30.2%-0.81%Within range
2022/Q24 Aug 2022Pre Market±19.3%+3.25%Within range
2022/Q15 May 2022Pre Market±18.0%+2.41%Within range
2021/Q43 Mar 2022Pre Market±24.1%-4.53%Within range
2021/Q34 Nov 2021Pre Market±22.2%+0.78%Within range
2021/Q25 Aug 2021Pre Market±25.5%+10.14%Within range
2021/Q15 May 2021Pre Market±27.3%-11.11%Within range
2020/Q44 Mar 2021Pre Market±39.6%-13.74%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$299,000.00-43.5% YoY
Operating profit-$10.27M-23.9% YoY
Net profit$59.12M+863.6% YoY
Diluted EPS$0.30+850.0% YoY
Free cash flow$239.81M+4,222.6% YoY
Operating cash flow$239.81M

Revenue, last 8 quarters

$1.6MDec '24$1.8MMar '25$10.7MJun '25$529.0KSep '25$1.1MDec '25$179.1MMar '26$1.0MJun '26$299.0KSep '26

Net profit, last 8 quarters

$-12.5MDec '24$-24.5MMar '25$2.5MJun '25$-7.7MSep '25$-3.8MDec '25$169.7MMar '26$-5.1MJun '26$59.1MSep '26

Profitability & balance sheet

Operating margin80.1%
Net margin121.2%
Return on equity269.6%
Return on assets100.6%
Return on invested capital264.0%
Current ratio1.40
Liabilities / assets74.8%
Cash & investments$337.49M
Total debt$0.00
Net cash (debt)$337.49M
Free cash flow / sales121.8%

Discussion

No comments yet — be the first to weigh in on ABUS.

Sign in to join the discussion.

Scroll to Top